THE WOODLANDS, Texas,
Oct. 17, 2012 /PRNewswire/ -- Lexicon
Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it
commenced an offering to sell, subject to market and other
conditions, shares of its common stock pursuant to an effective
shelf registration statement in an underwritten public
offering. Lexicon also intends to grant the underwriters a
30-day option to purchase additional shares of common stock to
cover over-allotments, if any. All of the shares in the
offering are to be sold by Lexicon. J.P. Morgan Securities
LLC and Jefferies & Company, Inc. will be acting as joint
book-runners for the offering.
This press release does not constitute an offer to sell, or the
solicitation of an offer to buy, these securities, nor will there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale is not permitted. The
offering of these securities will be made only by means of a
preliminary prospectus supplement and accompanying prospectus,
copies of which may be obtained from J.P. Morgan Securities LLC via
Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, New York 11717, or by
telephone at 866-803-9204, or from Jefferies & Company, Inc. at
520 Madison Avenue, 12th Floor, New York,
NY, 10022, Attention: Equity Syndicate Prospectus
Department, by calling (877) 547-6340 or by emailing
Prospectus_Department@Jefferies.com.
The issuer has on file with the Securities and Exchange
Commission, or SEC, an effective registration statement (including
a base prospectus) on Form S-3 for an offering to which this
communication relates. Before you invest, you should read the
prospectus in that registration statement and related prospectus
supplements and other documents that the issuer has filed or will
file with the SEC for more complete information about the issuer
and this offering. You may get these documents for free by
visiting EDGAR on the SEC website at www.sec.gov.
Alternatively, you may obtain a preliminary prospectus supplement
and accompanying prospectus as indicated above.
About Lexicon
Lexicon is a biopharmaceutical company focused on discovering
breakthrough treatments for human disease. Lexicon currently has
four drug programs in mid-stage development for diabetes, carcinoid
syndrome, irritable bowel syndrome and rheumatoid arthritis, all of
which were discovered by Lexicon's research team.
SOURCE Lexicon Pharmaceuticals, Inc.